Yongtao Li

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7220744/publications.pdf

Version: 2024-02-01

15	271	1040056	996975
papers	citations	9 h-index	15 g-index

15	15	15	430
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Building a Chemical Toolbox for Human Pregnane X Receptor Research: Discovery of Agonists, Inverse Agonists, and Antagonists Among Analogs Based on the Unique Chemical Scaffold of SPA70. Journal of Medicinal Chemistry, 2021, 64, 1733-1761.	6.4	15
2	Design, synthesis and biological assessment of novel CDK4 inhibitor with potent anticancer activity. Bioorganic Chemistry, 2021, 109, 104717.	4.1	4
3	Development of BODIPY FL VH032 as a High-Affinity and Selective von Hippelâ€“Lindau E3 Ligase Fluorescent Probe and Its Application in a Time-Resolved Fluorescence Resonance Energy-Transfer Assay. ACS Omega, 2021, 6, 680-695.	3.5	9
4	Development of BODIPY FL Thalidomide As a High-Affinity Fluorescent Probe for Cereblon in a Time-Resolved Fluorescence Resonance Energy Transfer Assay. Bioconjugate Chemistry, 2020, 31, 2564-2575.	3.6	8
5	Discovery of 12Oâ€”A Novel Oral Multi-Kinase Inhibitor for the Treatment of Solid Tumor. Molecules, 2020, 25, 5199.	3.8	3
6	CITCO Directly Binds to and Activates Human Pregnane X Receptor. Molecular Pharmacology, 2020, 97, 180-190.	2.3	24
7	Novel dual inhibitors targeting CDK4 and VEGFR2 synergistically suppressed cancer progression and angiogenesis. European Journal of Medicinal Chemistry, 2019, 181, 111541.	5.5	19
8	Drug discovery technologies to identify and characterize modulators of the pregnane X receptor and the constitutive androstane receptor. Drug Discovery Today, 2019, 24, 906-915.	6.4	17
9	Enhancement of Histone Deacetylase Inhibitor Sensitivity in Combination with Cyclin-Dependent Kinase Inhibition for the Treatment of Oral Squamous Cell Carcinoma. Cellular Physiology and Biochemistry, 2019, 53, 141-156.	1.6	8
10	Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)phenyl)-N8-hydroxyocta as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer. Journal of Medicinal Chemistry, 2018, 61, 3166-3192.	6.4	63
11	Highly Selective, Potent, and Oral mTOR Inhibitor for Treatment of Cancer as Autophagy Inducer. Journal of Medicinal Chemistry, 2018, 61, 881-904.	6.4	17
12	Selective and novel cyclin-dependent kinases 4 inhibitor: synthesis and biological evaluation. Medicinal Chemistry Research, 2018, 27, 1666-1678.	2.4	4
13	Novel hybrid molecule overcomes the limited response of solid tumours to HDAC inhibitors via suppressing JAK1-STAT3-BCL2 signalling. Theranostics, 2018, 8, 4995-5011.	10.0	48
14	A highly potent and selective inhibitor Roxyl-WL targeting IDO1 promotes immune response against melanoma. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, 1089-1094.	5.2	7
15	Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 3231-3237.	2.2	25